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Introduction:
With the exception of cyclic nucleotide gated channels in specialized cells like olfactory neurons (1) , the only known direct cAMP effector in mammalian cells was until recently the cAMP-dependent protein kinase (cAPK 1) ), whose mechanism of activation and structure has been studied in detail (2) (3) (4) .
It has been questioned whether cAPK is the sole mediator of cAMP action (5, 6) . The discovery (7, 8) of Rap guanine nucleotide exchange factors directly activated by cAMP (Epac1 and 2) raised the possibility that effects hitherto attributed to activation of cAPK were in fact mediated by Epac. Epac1 has a N-terminal DEP (Dishevelled, Egl-10, Pleckstrin) domain, involved in membrane docking (9) and cell adhesion (10), a cAMP binding domain (CNBD), a Ras exchange motif (REM), and a guanine nucleotide exchange factor (GEF) homology domain (Fig. 1A ). Epac2 has recently been crystallized (11). It has an additional CNBD (8) , which is dispensable for cAMP-induced Rap activation (9, 12) .
There is increasing, but still modest knowledge about the biological consequences of cAMP activation of endogenous Epac in intact cells. Epac appears not to mediate modulation of ERK activity by cAMP (13) , but may mediate the stimulation by cAMP of exocytosis (14, 15) , the calcitonin-induced H,K-ATPase activation in kidney cells (16) and modulate binding, the plates were incubated with buffer A (0.1 ml) and various concentrations of for Epac was in principle as previously described and validated for RI and RII (28) .
In vitro assay of Epac-induced Rap activation and cAMP-dependent protein kinase
activity -Cyclic AMP analogs were tested for in vitro Rap1 or Rap2 activation by determination of their effect on the rate of Epac-induced fluorescent GDP analog (3´-O-(N-methylantraniloyl)-GDP) exchange from Rap (9) . The determination of cAMP analog effects on protein kinase activity was routinely by incubation for 40 min at 37 °C in buffer A with 1 mM [γ-32 P]ATP, using kemptide as substrate (24) .
Assay of cAMP analog actions in intact cells -The activation of Rap was determined by
GST pull-down assay as described in (29) , except that NaF was omitted and 5 mM Mg(CH 3 COO) 2 added in lysis and wash buffers. The amount of immobilized Ral-GDS-7 fetal calf serum. The cells kept for 20 h in intact medium after seeding, and 1 h with low (5% horse and 2.5% fetal calf) serum, before being stimulated with cAMP analog or nerve growth factor (NGF) for 3 to 72 h, and fixed for evaluation by phase-and differential interference contrast microscopy (31). (Fig. 1D) .
Molecular modeling
We conclude that the CNBD of Epac has the same affinity for cAMP whether in a 170-residue peptide (Epac149-318) or included in the full length Epac molecule. Cyclic AMP analog mapping of the binding sites of Epac1, RI and RII was undertaken to probe for differences between the Epac and R subunit binding sites. We showed first that the estimated K´i of cAMP analogs for binding to Epac149-318 was similar whether assayed by the routine ammonium sulfate precipitation method or the equilibrium binding chromatography assay (Fig. 2 ).
Mapping data for analogs modified only in the adenine moiety are shown in Table 1 . We noted that the commonly used cAPK activators 8-Br-cAMP, 8-AHA-cAMP, and particularly 8-pCPT-cAMP had higher affinity than cAMP itself for Epac. No analog was severely restricted from binding to Epac, whereas several had very low K´i for binding to one or more of the binding sites of RIα (AI, BI) or RIIα (AII, BII). All the R subunit binding sites discriminated better than Epac against cGMP ( Table 1) . The modestly (12 fold) decreased K´i of cGMP for Epac was due to a combined effect of the introduction of 2-NH 2 and 6=O into the cAMP molecule ( Table 1) . The Sp-and Rp-diastereoisomers of cAMPS bound to Epac with a relative affinity similar to that for the cAPK sites ( Table 2 ).
The presumed cAPK-specific agonists Sp-8-pCPT-cAMPS and Sp-5,6-DCl-cBIMPS (33,34) bound to Epac with an affinity similar to that of cAMP itself ( Table 2 ).
The loss of the 2´-OH of cAMP was more detrimental for binding to cAPK than to Epac, since both 2´-deoxy-and 2´-O-alkyl-cAMP had higher K´i for Epac than for RI or RII (Table 2) . A more detailed survey of 8-substituted analogs of 2´-O-Me-cAMP indicated that the highest affinity was achieved when the S-phenyl ring was substituted in the paraposition with a polar group, like Cl, OH, O-methyl (Table 2) or F (not shown). All cAMP analogs modified in the 6-position of the adenine ring, including cPuMP, 6-ClcPuMP, cIMP, cGMP, 6-MB-cAMP, 6-Bnz-cAMP, and to a lesser extent 6-Phe-cAMP, were only partial Epac agonists (data for 6-Bnz-cAMP are shown in Fig. 6A ).
Comparison of cAMP analogs as modulators of cAPK and Epac activity in vitro and
Furthermore, the partial stimulation was observed at higher concentration than expected from the analog affinity for free Epac (not shown).
In fibroblasts with enforced expression of Rap1 and Epac1, the analogs 6-MB-cAMP and 6-Bnz-cAMP stimulated strongly the phosphorylation of the cAPK substrate CREB, but failed to activate Rap1 (not shown). Preferential stimulation by 6-modified cAMP analog of CREB phosphorylation was observed also in primary dog thyrocytes. In these cells rounding is a specific reaction to cAPK (5) . Cell rounding was induced by 6-MB-cAMP ( Fig. 7A ) and 6-Bnz-cAMP (not shown) without rap1 activation (Fig. 7A) . In contrast, 8-pCPT-cAMP and the adenylate cyclase activator forskolin induced Rap activation, CREB phosphorylation and cell rounding, and 8-pCPT-2´-O-Me-cAMP only Rap activation (Fig. 7A) . We conclude that 6-modified cAMP analogs, notably 6-Bnz-cAMP and 6-MBcAMP, may be useful to preferentially activate cAPK in intact cells. 
Discussion
The cAMP analog mapping revealed significant differences between the binding sites of to Glu324 in site BI (Fig. 10C ).
8-pCPT-2´-O-Me-cAMP and other 2´-O-alkyl analogs of cAMP were unable to activate cAPK fully under physiologically relevant conditions. This is a novel finding, and
indicates that 2´-O-Me-cAMP analogs are partial rather than full cAPK agonists. Even in the unlikely event that they should reach millimolar concentration inside the cell, they would be unable to activate cAPK above the normal resting level (20 -30% of full activity).
The CNBD of free Epac showed only partial discrimination (about 10-fold) between cAMP and cGMP ( Table 1 ). This would not be sufficient to prevent cGMP binding to Fig. 4 , except that hRIIα at 1 nM (❐), 15 nM (▲), 100 nM (❍), or 400 nM (◆) was present rather than RIα. 
